Sprint Bioscience Future Growth

Future criteria checks 0/6

Sprint Bioscience is forecast to grow revenue at 1.4% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	27.2%
Revenue growth rate	1.4%
Future return on equity	-3.0%
Analyst coverage	Low
Last updated	15 Feb 2025

Recent future growth updates

No updates

Recent updates

No updates

Earnings and Revenue Growth Forecasts

OM:SPRINT BTA - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	87	N/A	-11	-9	1
12/31/2026	179	N/A	82	84	1
12/31/2025	127	N/A	33	35	1
12/31/2024	66	-18	-25	-23	N/A
9/30/2024	61	-19	-23	-20	N/A
6/30/2024	86	15	21	24	N/A
3/31/2024	70	9	13	16	N/A
12/31/2023	52	0	20	23	N/A
9/30/2023	40	-10	10	10	N/A
6/30/2023	0	-52	-44	-44	N/A
3/31/2023	0	-58	-48	-48	N/A
12/31/2022	0	-60	-59	-59	N/A
9/30/2022	1	-60	-59	-59	N/A
6/30/2022	35	-30	-30	-28	N/A
3/31/2022	35	-26	-42	-41	N/A
12/31/2021	35	-25	-43	-40	N/A
9/30/2021	35	-25	-36	-33	N/A
6/30/2021	8	-48	-62	-61	N/A
3/31/2021	14	-47	-48	-47	N/A
12/31/2020	19	-43	-32	-32	N/A
9/30/2020	23	-39	-35	-35	N/A
6/30/2020	21	-40	-18	-18	N/A
3/31/2020	35	-23	-12	-12	N/A
12/31/2019	34	-22	-28	-28	N/A
9/30/2019	21	-31	-27	-35	N/A
6/30/2019	19	-33	-48	-52	N/A
3/31/2019	3	-47	-52	-53	N/A
12/31/2018	18	-32	-30	-29	N/A
9/30/2018	31	-19	N/A	-20	N/A
6/30/2018	32	-15	N/A	-12	N/A
3/31/2018	41	-5	N/A	-7	N/A
12/31/2017	33	-11	N/A	-23	N/A
9/30/2017	41	-1	N/A	-19	N/A
6/30/2017	47	5	N/A	6	N/A
3/31/2017	53	8	N/A	7	N/A
12/31/2016	47	5	N/A	8	N/A
9/30/2016	40	-2	N/A	8	N/A
6/30/2016	34	-5	N/A	0	N/A
3/31/2016	17	-14	N/A	-1	N/A
12/31/2015	13	-15	N/A	1	N/A
9/30/2015	10	-15	N/A	2	N/A
6/30/2015	6	-15	N/A	-14	N/A
3/31/2015	6	-13	N/A	-11	N/A
12/31/2014	5	-11	N/A	-11	N/A
9/30/2014	5	-9	N/A	-8	N/A
6/30/2014	5	-7	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SPRINT BTA's forecast earnings growth is above the savings rate (1.3%).

Earnings vs Market: Insufficient data to determine if SPRINT BTA's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if SPRINT BTA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SPRINT BTA's revenue (1.4% per year) is forecast to grow slower than the Swedish market (4.2% per year).

High Growth Revenue: SPRINT BTA's revenue (1.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SPRINT BTA is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/05 06:50
End of Day Share Price	2025/05/05 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sprint Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Siri Ladow	Danske Bank
Johan Unnerus	Redeye